Vidaza

Selected form

Azacitidine

Method of action: Antitumour

Treatment option: Dysplasia, Leukemia, Myelodysplastic Diseases, Leukemia, Acute Granulocytic, Blood Cell Transplantation

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vidaza

Vidaza is the established brand name for a specialized, prescription-only injectable medicine used in the treatment of certain blood and bone marrow disorders. Its active component is the synthetic chemical entity known as Azacitidine (5-azacytidine), structurally defined as a pyrimidine nucleoside analog.

Property	Description
Active ingredient	Azacitidine (INN: 5-azacytidine)
Form	Powder for injection (Lyophilized)
Pharmacological class	Antineoplastic Agent, Hypomethylating Agent
Origin	Synthetic chemical entity (Pyrimidine nucleoside analog)
Parenteral Route	Subcutaneous (SC) or Intravenous (IV)

Defining Azacitidine: Identity and Composition

Azacitidine is a single-agent product supplied as a sterile lyophilized powder for injection that must be reconstituted for parenteral administration via subcutaneous injection or intravenous infusion. The regulatory approval of this formulation established its position as a therapy for serious hematological conditions. The medicine requires meticulous handling and professional administration, distinguishing its use from patient-managed oral therapies.

Pharmacological Classification and Mechanism Type

Vidaza is definitively categorized as an antineoplastic agent due to its role in counteracting the growth of abnormal cells. More specifically, its core identity is that of a hypomethylating agent and an inhibitor of the DNA methyltransferase (DNMT) enzyme. This classification indicates that Azacitidine operates as a specialized form of epigenetic therapy, a mechanism recognized for its ability to alter the chemical signals surrounding DNA (methylation) that control gene expression. This approach demonstrates a unique ability to modify how genes responsible for cellular growth and maturation are expressed.

General Therapeutic Purpose

The overarching purpose of Azacitidine’s action is to help regulate and stabilize the function of the blood-forming tissue within the bone marrow. Its fundamental mechanism promotes differentiation, facilitating the maturation of abnormal, immature blood cells into functional cells. By intervening in these processes, the therapy works to support better order and improved function of the patient’s blood system.

Regulatory References

What side effects are possible with Vidaza?

Possible side effects and safety information for Vidaza

The official regulatory safety profile for Azacitidine is organized by frequency and organ system, outlining the officially documented adverse reactions.

Category	Regulatory Documentation
Key adverse reaction categories	Myelosuppression (including Anemia, Neutropenia, and Thrombocytopenia), Gastrointestinal disorders, and Injection site reactions.
Frequency classification (Very Common)	Adverse events affecting 1 in 10 patients or more include low blood cell counts, Nausea, Vomiting, Diarrhea, Constipation, Pyrexia (fever), Fatigue, and local reaction at the injection site (erythema, pain, bruising).
System-organ classes involved	Officially cited affected systems include Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Infections and Infestations, and General Disorders and Administration Site Conditions.
Serious adverse reactions	Officially documented serious reactions include Febrile Neutropenia, potentially fatal cases of Sepsis and Hepatic Failure, Necrotizing Fasciitis, and Tumor Lysis Syndrome (TLS).
Population-specific safety considerations	Azacitidine is officially contraindicated during Lactation and can cause fetal harm if used during Pregnancy. Caution is advised for patients with severe pre-existing hepatic impairment and those with renal impairment.
Exposure-related patterns	The highest risk of low blood cell counts (haematological toxicity) is documented to occur during the initial cycles of treatment.
Safety-related restrictions	The medicine is contraindicated in individuals with a known hypersensitivity to Azacitidine or mannitol, and in those with advanced malignant hepatic tumors.

Safety classifications (high-level)

The regulatory safety summary explicitly documents that monitoring of complete blood counts, liver chemistries, and serum creatinine is required prior to and throughout treatment to monitor for toxicity. The safety profile is established and continuously monitored by government authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Connection to the overall safety profile

This framework of official safety information clearly defines that the most frequent events involve the reduction of blood cells and common physical reactions, while specifically identifying less common but critical serious adverse reactions. The profile emphasizes that the risk of low blood counts is highest during the early phase of treatment and explicitly restricts use based on specific patient conditions defined in regulatory labels.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Azacitidine (Vidaza) overdose strictly defines the necessary emergency actions and documented clinical presentations. Any instance of a suspected drug overdose requires the immediate, mandated action of contacting a regional poison control centre for professional management. This reflects the requirement for prompt assessment based on the drug's properties.

The clinically documented manifestations of overdose are based on findings from a single reported case during clinical trials, which involved exposure to a single intravenous dose approximately four times the recommended starting dose. The officially recorded signs involve the gastrointestinal system and include diarrhea, nausea, and vomiting.

Official management procedures underscore supportive care and mandatory monitoring. Regulatory labeling explicitly states that there is no known specific antidote for a Vidaza overdose. Consequently, management focuses on procedural steps: the patient must be monitored with appropriate blood counts, and supportive treatment should be administered as necessary. No specific guidance on increased overdose severity is explicitly detailed for populations such as the elderly or those with hepatic or renal impairment in the official overdose sections.

Therapeutic Uses of Vidaza

What Vidaza Treats: Main Uses and Benefits

Vidaza is a medication primarily applied across therapeutic domains that involve specific, higher-risk blood and bone marrow disorders. It is applied across domains where additional symptomatic support is needed.

Condition Categories: Targeting Myelodysplastic Syndromes (MDS)

This medicine is commonly used across conditions characterized by periods of heightened symptoms, specifically high-risk Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and certain related hematologic conditions. Its use contributes to improving day-to-day comfort, and is considered relevant in conditions where symptoms may intensify temporarily.

Symptom Groups: Addressing Hematologic Instability

The treatment helps address symptom clusters that may become intense or disruptive that arise from low blood cell counts, such as those that lead to anemia, neutropenia, and thrombocytopenia. It provides support that helps ease the overall burden of symptoms that interfere with daily functioning, such as fatigue and weakness. “Offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Support for Functional Strain

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, and is often used when supportive symptom management is appropriate. In these settings, it is applied in addressing the potential for temporary functional strain, supporting the patient during difficult episodes and assisting with maintaining a sense of stability.

Regulatory References

European Medicines Agency (EMA) overview of Vidaza

Eligibility and Restrictions for Use

This section summarizes the official rules from government regulatory bodies (such as the FDA and EMA) regarding which patient populations are eligible to use Vidaza (azacitidine) and which are prohibited.

Contraindications (Who Must Not Use Vidaza)

Vidaza is strictly contraindicated and must not be used in the following populations, as stated in regulatory labeling:

Patients with a known hypersensitivity to azacitidine or mannitol (an excipient).
Patients with advanced malignant hepatic tumors.
Women who are breastfeeding.

Age-Specific Eligibility

Age Group	Eligibility Status
Adults	Approved for the treatment of specific Myelodysplastic Syndromes (MDS) subtypes and Acute Myeloid Leukemia (AML) in certain contexts.
Pediatrics	Approved for patients aged one month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML). Use for other pediatric conditions is not established.
Older Adults	No specific dose adjustment is typically required, but renal function should be closely monitored due to the higher likelihood of decreased function in this population.

Condition-Based Restrictions

Hepatic Impairment: Patients with severe pre-existing hepatic impairment require close monitoring due to an increased risk of toxicity. Use is contraindicated in patients with advanced malignant hepatic tumors.
Renal Impairment: Patients with kidney impairment must be closely monitored for toxicity (e.g., serum creatinine, BUN) as the drug is primarily excreted by the kidneys; dose modifications may be required if toxicity occurs.
Pregnancy: Vidaza is not recommended for use during pregnancy as it can cause fetal harm. Female and male patients of reproductive potential must use effective contraception during and after treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information indicates that formal drug-drug interaction studies between Vidaza (azacitidine) and other medicines have not been conducted by the manufacturer. Consequently, official labeling does not provide a list of interacting medicinal products or substance classes.

Mechanistic Considerations and Constraints

While formal studies are absent, azacitidine is primarily cleared from the body through spontaneous hydrolysis and deamination mediated by cytidine deaminase, and it is substantially excreted by the kidneys. The potential for azacitidine to inhibit or induce Cytochrome P450 (CYP) enzymes, a major pathway for drug metabolism, is unknown.

Population and Condition-Specific Notes

Patients with renal impairment should be monitored closely for toxicity since azacitidine and its metabolites are excreted mainly via the kidneys, which may increase the risk of adverse reactions. Similarly, caution is advised for patients with pre-existing severe hepatic impairment due to the potential for increased toxicity.

Patients with a history of severe congestive heart failure, clinically unstable cardiac disease, or pulmonary disease were excluded from pivotal clinical trials, meaning the safety profile in these specific populations has not been established and close observation is warranted.

Mechanism of Action

How Vidaza Works

Azacitidine (Vidaza) operates through epigenetic modulation, altering chemical signals that control gene expression without modifying the DNA sequence. Its mechanism is centered on two closely linked biological domains: the inhibition of DNA methylation and the resulting modulation of differentiation pathways.

Inhibiting DNA Methyltransferase (DNMT)

The drug's primary action is the covalent inhibition of the DNA methyltransferase 1 (DNMT1) enzyme. Azacitidine is incorporated into the DNA of rapidly dividing cells, which causes it to irreversibly trap the DNMT1 enzyme, leading to its functional depletion. This molecular event drives global DNA hypomethylation—the reversal of aberrant chemical marks that silence key genetic programs.

Restoring Cell Maturation and Growth Control

The resulting hypomethylation reactivates previously silenced growth-control and differentiation genes that are essential for the orderly production of blood cells. This effect promotes the re-expression of differentiation pathways, resulting in the maturation of hematopoietic precursor cells. The re-expression of these genes influences cell regulation within the hematopoietic tissue.

Dosage and Administration Information

Instruction Map: How to use Vidaza

Administration of Vidaza (azacitidine) must be conducted under the supervision of a physician experienced in chemotherapy. Prior to receiving the injection, patients should be premedicated for nausea and vomiting.

Administration Scope

Classification	Detail
Route of Administration	Subcutaneous (SC) injection or Intravenous (IV) infusion.
Dosing Schedule	75 mg/m^2 of body surface area daily for 7 days.
Frequency Pattern	A 28-day cycle: 7 daily doses followed by a 21-day rest period.
Timing in relation to meals	Not applicable (Non-oral route of administration).

Procedural and Adjustment Rules

Classification	Detail
Preparation Requirements	The powder is reconstituted with Sterile Water for Injection, USP. The vial must be shaken vigorously to achieve a cloudy suspension for SC use or a clear solution for IV use. Doses >4 mL must be divided for SC injection into separate sites.
Age-Group Rules	The recommended starting dose (75 mg/m^2) applies to adults. Specific IV dosing guidelines exist for pediatric patients (ge 1 month) with Juvenile Myelomonocytic Leukemia (JMML).
Missed-Dose Rules	A missed dose should not be given at the same time as the next scheduled dose, but should be added to the end of the current dosing cycle.
Dose Adjustment Rules	Dosage may be increased to 100 mg/m^2 after two cycles if no beneficial effect and no toxicity other than nausea/vomiting is observed. Dose delay or reduction (often by 50%) is mandatory based on specific hematologic and renal toxicity criteria (e.g., lack of blood count recovery by Day 42, or unexplained reductions in serum bicarbonate).

Treatment should continue for at least 4 to 6 cycles and proceed as long as the patient continues to benefit. All patients must have complete blood counts, liver chemistries, and serum creatinine monitored prior to the first dose and before each subsequent cycle.

Recent Clinical Evidence

Research evidence / Overview of Studies for Azacitidine (Vidaza)

Evidence for Use in Higher-Risk Myelodysplastic Syndromes (MDS)

The initial clinical evaluation of Azacitidine was used in research exploring how symptoms change over time in adult patients diagnosed with Higher-Risk Myelodysplastic Syndromes (MDS). The evidence is largely based on Randomized Controlled Trials (RCTs)—studies designed to compare Azacitidine against standard non-intensive care or observation alone. Researchers used these trials to examine outcomes related to systemic or functional imbalance.

These studies monitored specific outcomes, including Overall Survival (the total time patients remained alive after the study began) and the time to transformation of MDS into Acute Myeloid Leukemia (AML). Studies also explored outcomes reflecting daily functioning by examining the achievement of transfusion independence. Studies monitored changes measured during the defined study period and reported patterns observed in the symptom evolution of the observed populations.

Certainty remains low regarding the degree to which these findings were replicated across all subsequent research. Research describes that the early study designs included provisions for patients in the control group to sometimes switch to receiving Azacitidine, a factor which was noted in the assessment of long-term survival outcomes.

Evidence for Use in Acute Myeloid Leukemia (AML)

Research for Azacitidine in Acute Myeloid Leukemia (AML) primarily involved studies in a specific group: older adults who were observed in studies examining patient-reported experiences and were not candidates for intensive, high-dose chemotherapy due to age or other health issues. These studies compared Azacitidine against other conventional care regimens in this distinct population.

Studies explored outcomes related to physical discomfort by monitoring Overall Survival in this specific, frailer group. Findings also tracked Overall Response Rate, which measures how many patients achieved a Complete Remission (CR) or a related state where blood cell counts improved significantly. Data show patterns related to how many patients achieved freedom from transfusions.

Research is ongoing, and the landscape is defined by the continued study of combination therapies, which affects the context of single-agent research findings. Comparative evidence is lacking for head-to-head comparisons of single-agent Azacitidine against other non-intensive agents.

What Remains Uncertain About Azacitidine Research

Long-term effects are not fully established, and evidence is limited regarding the maximum duration an individual patient may sustain a measured response. The evidence for certain patient groups, such as children or younger adults, is more limited. Furthermore, the consistency of the survival findings has been described as mixed in various post-hoc analyses and meta-reviews, meaning that not all studies perfectly replicated the initial trial results. Evidence highlights what is known—and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Vidaza (FAQ)

Q: Is Vidaza classified as traditional chemotherapy?

Official regulatory documents classify Vidaza (azacitidine) as an antineoplastic agent, which means it works against the growth of abnormal cells. More specifically, it is described as a hypomethylating agent or epigenetic modulator. This indicates that the drug targets the chemical signals (methylation) that control gene expression, a mechanism distinct from some conventional cytotoxic chemotherapy.

Q: How long does it take for Vidaza to start showing effects in the body?

Regulatory guidance indicates that Vidaza treatment is typically assessed after several cycles. The initial recommended course of treatment is at least 4 to 6 cycles. Official labeling allows healthcare providers to consider increasing the dose after 2 treatment cycles if a beneficial effect has not yet been observed and the drug has not caused significant toxicity.

Q: What is the expected 'nadir' or lowest point for blood cell counts after a cycle?

Regulatory guidance defines the need to closely monitor blood counts for toxicity during treatment. The lowest blood cell counts (nadir) observed during a cycle are monitored to guide potential dose modifications in subsequent cycles, according to official criteria. Official criteria define specific laboratory thresholds for blood counts that, if met, indicate the need for a healthcare provider to assess whether a dose modification or delay is necessary for the next cycle.

Q: Does Vidaza commonly cause hair loss?

Official safety data lists Alopecia (hair loss) as an uncommon side effect. This means the effect is described as infrequent in the regulatory safety data.

Q: Is nausea a frequent side effect, and is it manageable?

Nausea is listed as a Very Common side effect, meaning it affects more than 1 in 10 patients. Due to this high frequency, official instructions describe the need for premedication for nausea and vomiting prior to the first dose of a cycle.

Q: Are headaches a common complaint for people on Vidaza?

According to official safety data, Headache is classified as a Common side effect. This effect is reported in up to 10% of patients in official safety data.

Q: Is Vidaza the same medication as the oral form of azacitidine (Onureg)?

Vidaza is the brand name for the injectable formulation of azacitidine, which is administered as a subcutaneous shot or intravenous infusion. A separate oral formulation of azacitidine (e.g., Onureg) has been approved by regulatory agencies for a different, specific purpose, such as maintenance therapy for Acute Myeloid Leukemia (AML) following initial chemotherapy.

Q: How does the administration route (subcutaneous vs. intravenous) affect side effects?

While many systemic side effects are generally the same regardless of the administration route, official clinical trial data lists Injection site erythema (redness) as a Very Common adverse reaction. This specific local reaction is typically associated with the subcutaneous (under the skin) route of administration.

Q: Does Vidaza affect the ability to drive or operate machinery?

Regulatory product information notes that if side effects such as tiredness (fatigue) or dizziness occur, the ability to drive or operate machinery may be affected.

Q: Is anxiety or sleep difficulty a known side effect of Vidaza?

Official safety information lists both Anxiety and Insomnia (trouble sleeping) as Common side effects of Vidaza. This effect is reported in up to 10% of patients in clinical studies.

Q: Does Vidaza affect fertility in men or women?

Official regulatory warnings address the drug's potential impact on reproductive health. Men receiving Vidaza are advised to avoid fathering a child during treatment and for a period up to 3 months after treatment cessation. Prior to starting treatment, male patients may consider seeking counseling regarding the option of sperm storage.

Q: What does 'hematologic improvement' mean when assessing Vidaza effectiveness?

In clinical trials, hematologic improvement is a key measure used to assess the drug's effectiveness. This generally refers to the goal of achieving a better state of blood cell production and function. Outcomes that reflect this improvement include achieving a Complete Response (CR), a Partial Response (PR), and achieving transfusion independence.

Q: Does Vidaza treat all subtypes of Myelodysplastic Syndrome (MDS)?

Vidaza is indicated for the treatment of specific subtypes of Myelodysplastic Syndrome in adults, based on the French-American-British (FAB) classification system. Vidaza is indicated for several specific subtypes of MDS, classified by the French-American-British (FAB) system, which include various forms of refractory anemia and chronic myelomonocytic leukemia (CMMoL).

How should Vidaza be stored and disposed of?

The official storage and disposal guidelines for Vidaza (Azacitidine) are defined by its nature as a cytotoxic, lyophilized powder.

Storage Requirements

Unopened Powder: The vials of lyophilized powder must be stored at Controlled Room Temperature (25 C), with permitted excursions between 15 C and 30 C.
Reconstituted Suspension: The suspension prepared for injection has strict stability limits. It must be used within one hour if kept at room temperature, or stored under refrigeration (2 C to 8 C) for up to mathbf8 to mathbf22 hours, depending on the preparation method.
Safety: The medicine must be kept out of the sight and reach of children.

Disposal and Handling

Vidaza is classified as a cytotoxic/hazardous drug. Handling and administration must follow specific safety procedures to minimize exposure. Disposal of all unused medicine and waste material is mandatory and must strictly comply with local, governmental regulations for cytotoxic or hazardous agents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.